



PFW  
PATENT


Case Docket No. NEREUS.069A  
Date: September 13, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Mitchell, et al.  
Appl. No. : 10/673,036  
Filed : September 25, 2003  
For : MACROCYCLIC LACTAMS  
Examiner : Kifle, Bruck  
Group Art Unit : 1624

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 13, 2004

  
(Date)

Marc T. Morley, Reg. No. 52,051


TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement in one (1) page.
- (X) A PTO Form 1449 listing and enclosing thirteen (13) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.



Marc T. Morley  
Registration No. 52,051  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550



## INFORMATION DISCLOSURE STATEMENT

Applicant : Mitchell, et al.  
App. No. : 10/673,036  
Filed : September 25, 2003  
For : MACROCYCLIC LACTAMS  
Examiner : Kifle, Bruck  
Group Art Unit : 1624

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing thirteen (13) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 9/13/04

By: Marc T. Morley

Marc T. Morley  
Registration No. 52,051  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. NEREUS.069A	APPLICATION NO. 10/673,036
O P E R A T I O N INFORMATION DISCLOSURE STATEMENT BY APPLICANT SEP 15 2004 (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Mitchell, et al.	
		FILING DATE September 25, 2003	GROUP 1624

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
1	Alm, et al. "Effects of topically Applied PGF <sub>2α</sub> and its Isopropylester on Normal and Glaucomatous Human Eyes." <i>Prog. Clin. Biol. Res.</i> 312: 447-58 (1998).	
2	"Bioreversible Carriers in Drug Design: Theory and Application," edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987).	
3	Fenical, William. "Chemical Studies of Marine Bacteria: Developing a New Resource." <i>Chem. Rev.</i> 93:1673-1683 (1993).	
4	Fingl, et al. <i>Basis of Therapeutics</i> . 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 13. "Drugs Effective in the Therapy of the Epilepsies," (1975).	
5	Fingl, et al. <i>Basis of Therapeutics</i> . 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 17. "Analgesic-Antipyretics, Anti-Inflammatory Agents, and Drugs Employed in the Therapy of Gout," (1975).	
6	Fingl, Edward. <i>Basis of Therapeutics</i> . 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 49. "Laxatives and Cathartics," (1975).	
7	Higuchi, et al. "Pro-drugs as Novel Delivery Systems." <i>A.C.S. Symposium Series</i> , American Chemical Society. 14(3): 154-183 (1975).	
8	Joshi, A. "Microparticulates for Ophthalmic Drug Delivery." <i>J. Ocul. Pharmacol.</i> , 10(1):29-45 (1994).	
9	Khokhlova, et al. "A Chemical Study of the Major Vitamycin Component." Institute of Microbiology, Academy of Sciences of the USSR, Moscow, pgs. 841-845, Russian (1964).	
10	Krassilnikov, et al. "A New Species in the Group of <i>Actinomyces Aurantiacus</i> ," pgs. 482-489 (1960).	
11	Mayer et al. "Efficacy of a Novel Hydrogel Formulation in Human Volunteers." <i>Ophthalmologica</i> . 210(2):101-3 (1996).	
12	Mordini, et al. "Intraocular Pharmacokinetics and Safety of a Humanized Monoclonal Antibody in Rabbits after Intravitreal Administration of a Solution or a PLGA Microsphere Formulation." <i>Toxicol. Sci.</i> 52(1):101-6 (1999).	
13	Shedden, et al. "Efficacy and Tolerability of Timolol Maleate Ophthalmic Gel-Forming Solution Versus Timolol Ophthalmic Solution in Adults with Open-Angle Glaucoma or Ocular Hypertension: A Six-Month, Double-Masked, Multicenter Study." <i>Clin. Ther.</i> , 23(3): 440-50 (2001).	

S:\DOCS\MTM\MTM-6823.DOC sma090204

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	